Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 08/05/13 | 8-K | Current report filing |
|
28 | |
| 06/19/13 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 06/19/13 | DEF 14A | Definitive proxy statements |
|
24 | |
| 06/04/13 | 424B4 | Prospectus filed pursuant to Rule 424(b)(4) |
|
101 | |
| 05/31/13 | EFFECT | Notice of Effectiveness |
|
1 | |
| 05/31/13 | UPLOAD | SEC-generated letter |
|
1 | |
| 05/20/13 | CORRESP | A correspondence can be sent as a document with another submission type or can be sent as a separate submission. |
|
2 | |
| 05/20/13 | POS AM | Post-effective amendment to a registration statement that is not immediately effective upon filing |
|
   |
110 |
| 05/15/13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) |
|
|
36 |
| 05/14/13 | 8-K | Current report filing |
|
12 |
